NEUROP, INC.

ATLANTA, GA · Biotech · Private

NP10679, a selective GluN2B NMDAR inhibitor small molecule for preventing delayed cerebral ischemia after subarachnoid hemorrhage

New patent · Sep 29

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: ATLANTA, GA
Latest Form D: $155K, Feb 2014
Total capital: $7.7M

Federal grants: $7.5M; 5 awards · 2017–2019; Rank in peer group#84 of 514
Private capital raised: $155K; 1 Form D · last Feb 2014; 152 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 2; 4 pending · first 2025; Rank in peer group#142 of 514

Capital timeline

Latest events

Mar 2019Federal grantHealth and Human S · Phase II · Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$125K
Aug 2018Federal grantHealth and Human S · Phase II · Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$1.3M
Jul 2018Federal grantHealth and Human S · Phase I · Preclinical assessment of the GluN2B inhibitor clinical candidate NP10679 as a medication to prevent opiate abuse relapse$301K
Aug 2017Federal grantHealth and Human S · Phase II · Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective,Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$3.6M
Jul 2017Federal grantHealth and Human S · Phase II · Phase 1 Clinical Evaluation of NP10679, a GluN2B Selective, Context-Dependent NMDA Receptor Inhibitor for Subarachnoid Hemorrhage$2.2M
Feb 2014Private capital raisedForm D · SEC · 1st filing$155K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#84 · top 16%
Granted patents#142 · top 28%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Dennis LiottaResearcherDirectorLinked by 1 patent
George KoszalkaExecutive Officer, DirectorNamed in SEC Form D filings
James McNamaraDirectorNamed in SEC Form D filings
Raymond DingledineDirectorNamed in SEC Form D filings
Robert BonczekDirectorNamed in SEC Form D filings

What it has protected

USPTO · 2 granted of 6

Sep 29, 2026New patentGLUN2B-SUBUNIT Selective Antagonists Of The N-methyl-d-aspartate Receptors With Enhanced Potency At Acidic PhUSPTOUS 12,747,221
Sep 16, 2025GrantedGLUN2B-SUBUNIT Selective Antagonists Of The N-methyl-d-aspartate Receptors With Enhanced Potency At Acidic PhUSPTOUS 12,415,790
Oct 31, 2024PendingGLUN2B-SUBUNIT Selective Antagonists Of The N-methyl-d-aspartate Receptors With Enhanced Potency At Acidic PhUSPTOApplication 18688300

Show all 6 patent records

GLUN2B-SUBUNIT Selective Antagonists Of The N-methyl-d-aspartate Receptors With Enhanced Potency At Acidic PhSep 29, 2026 · US 12,747,221Granted
GLUN2B-SUBUNIT Selective Antagonists Of The N-methyl-d-aspartate Receptors With Enhanced Potency At Acidic PhSep 16, 2025 · US 12,415,790Granted
GLUN2B-SUBUNIT Selective Antagonists Of The N-methyl-d-aspartate Receptors With Enhanced Potency At Acidic PhOct 31, 2024 · Application 18688300Pending
Compounds For The Treatment Of Neurological DisordersApplication PCTUS2013040408Pending
Compounds For The Treatment Of Neurologic DisordersApplication PCTUS2010060571Pending
Nmda Receptor Antagonists For NeuroprotectionApplication PCTUS2008068843Pending

Turn Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
Codebreaker Tx, Inc.Similar federal contract value in Biotech · null in contracts
VERALOX THERAPEUTICS, INCSimilar federal contract value in Biotech · null in contracts
Axiom Therapeutics Inc.Similar federal contract value in Biotech · null in contracts
FluidForm Bio, Inc.Similar federal contract value in Biotech · null in contracts
ANTICANCER, INC.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.